The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
Chronic kidney disease (CKD) affects an estimated 10% of the world (opens in a new tab), which is just under 800 million people.
According to the US-based National Kidney Foundation (opens in a new tab), 90% of people affected by the disease don’t know they have it at the early stages, allowing it to progress undetected.
In some cases, CKD is caught only at “end stage,” when kidneys are failing and require either a transplant or dialysis — a grueling, weekly procedure to remove waste and excess fluid from the blood. The average survival rate of dialysis patients is five years.
Curespec (opens in a new tab), based in Yehud-Monosson in Israel, claims its unique device, Nephrospec, can postpone the dialysis treatment of stage three and four CKD patients by up to 12 months.
Curespec is a biotech company working to improve treatments for chronic kidney disease and hypertension. Company CEO Rotem Kaynan is a Technion alumnus.